POS1517 MICROANGIOPATHY, INDEPENDENT RISK FACTOR FOR DAMAGE ACCRUAL IN ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE MULTI-CENTER STUDY

Background Antiphospholipid syndrome is characterized from venous, arterial and small vessels thromboembolic events leading to significant morbidity mortality despite current treatments. Albeit, the acute diseases manifestations of antiphospholipid are well known, data on damage accrual still lacking. Objectives To assess frequency in (APS) evaluate association with different laboratory clinical APS subsets. Methods Medical records 274 patients, 231 (84.3%) female 43 (15.7%) males a mean (±SD) age at diagnosis 37.8 (±11.5) years, followed prospectively 1990 2021, were reviewed. Results Ninety-six (35%) presented pregnancy alone, 140 (51.1%) thrombosis alone 38 (13.9%) both morbidity. A single, double or triple antibodies (aPL) positivity was registered, respectively in, 82 (29.9%), 78 (28.5%) 114 (41.6%) patients. Following follow up 208.4 (±91.7) months, total 58 (21.2%) organ recorded. This included neurological 19 (32.8%) hemiparesis 9, epilepsy 7 cognitive dysfunction/dementia three cases, cardiac valvopathy 4 (6.9 %) patients which 3/4 (75%) require valve replacement mechanical two cases bioprosthetic one. Chronic heart failure found (6.9%) chronic renal 15 (25.9%), amputation due peripheral 5 (8.6%), visual loss 2 (3.4%), post thrombotic 6 (10.3%), adrenal insufficiency one (1.7%). Some present more than disfunction. Both subsets significantly associated higher rate compared p<0.0001 (OD 40.7; 95% CI: 6.9-418.8) 61.9; CI 10.5-659.7). Moreover, presence microangiopathy as venous accrual, (p<0.0001, OD 10.99; 5.7-21-36) (p=0.001). Regarding subsets, aPL single aPL, respectively, 9.6; 3.7-23.5) 4.8; 2.2-10.81). At multivariate analysis only an independent risk factor for Conclusion Overall, our show Microangiopathy accrual. These findings should be mind when counselling might help guide clinicians therapeutic decision. References [1] Cervera R, Serrano Pons-Estel GJ, et al. Ann Rheum Dis 2015;74:1011–1018. doi:10.1136/annrheumdis-2013-204838 [2] Taraborelli M, Reggia Dall’Ara R J Rheumatol 2017;44:1165–1172. doi:10.3899/jrheum.161364. Acknowledgements: NIL. Disclosure Interests None Declared.